GlassScriptPhysician profile
Bridget T Carey
NPI 1417998436
$1,988.99
in general payments reported to CMS, 2019-2025
21 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $49.66 · 2021: $328 · 2022: $459 · 2023: $457 · 2024: $447 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,151.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $401.82 | 2023-2025 | |
| Mannkind Corporation | $397.29 | 2020-2025 | Afrezza |
| Lilly USA, LLC | $223.88 | 2023-2025 | Amyvid, Kisunla |
| Grt US Holding, INC. | $165.62 | 2021-2022 | |
| Medtronic, INC. | $140.30 | 2021 | |
| Grifols USA, LLC | $106.94 | 2023-2025 | Gamunex-C |
| Biogen, INC. | $101.29 | 2021-2023 | Aduhelm |
| Currax Pharmaceuticals LLC | $68.58 | 2022-2023 | Onzetra Xsail |
| Argenx US, INC. | $59.56 | 2022-2023 | Vyvgart |
| Biohaven Pharmaceutical Holding Company LTD. | $59.27 | 2022 | |
| Novo Nordisk INC | $52.83 | 2020-2023 | Rybelsus, Ozempic |
| Nevro Corp. | $47.67 | 2022-2023 | Senza |
| Cequr Corporation | $23.64 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $21.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.86 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.33 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $16.99 | 2023 | Evkeeza |
| Almatica Pharma LLC | $16.73 | 2023 | Gralise |
| Madrigal Pharmaceuticals | $16.31 | 2025 | Rezdiffra |
| Abbvie INC. | $14.36 | 2020 | |
| Avion Pharmaceuticals | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.